BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 27784171)

  • 1. Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies.
    Qu W; Li J; Duan P; Tang Z; Guo F; Chen H; Zhu X; Jiang SW
    Expert Rev Mol Diagn; 2016 Dec; 16(12):1271-1282. PubMed ID: 27784171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of human epididymis protein 4 as a biomarker in gynecologic malignancies.
    Plotti F; Scaletta G; Terranova C; Montera R; De Cicco Nardone C; Luvero D; Rossini G; Gatti A; Schirò T; Moncelli M; Guzzo F; Angioli R
    Minerva Ginecol; 2019 Feb; 71(1):36-43. PubMed ID: 30318876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HE4-test of urine and body fluids for diagnosis of gynecologic cancer.
    Qu W; Gao Q; Chen H; Tang Z; Zhu X; Jiang SW
    Expert Rev Mol Diagn; 2017 Mar; 17(3):239-244. PubMed ID: 28117603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers.
    Li J; Chen H; Curcuru JR; Patel S; Johns TO; Patel D; Qian H; Jiang SW
    Curr Drug Targets; 2017; 18(10):1158-1164. PubMed ID: 28382859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review.
    Scaletta G; Plotti F; Luvero D; Capriglione S; Montera R; Miranda A; Lopez S; Terranova C; De Cicco Nardone C; Angioli R
    Expert Rev Anticancer Ther; 2017 Sep; 17(9):827-839. PubMed ID: 28756722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors.
    Cymbaluk-Ploska A; Chudecka-Glaz A; Surowiec A; Pius-Sadowska E; Machalinski B; Menkiszak J
    Asian Pac J Cancer Prev; 2016; 17(5):2597-603. PubMed ID: 27268637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4.
    Capriglione S; Plotti F; Miranda A; Lopez S; Scaletta G; Moncelli M; Luvero D; De Cicco Nardone C; Terranova C; Montera R; Angioli R
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):9-18. PubMed ID: 27892774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of serum and tissue HE4 expression in ovarian cancer: a systematic review with meta-analysis of 90 studies.
    Cao H; You D; Lan Z; Ye H; Hou M; Xi M
    Expert Rev Mol Diagn; 2018 Apr; 18(4):371-383. PubMed ID: 29569984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis.
    Bie Y; Zhang Z
    World J Surg Oncol; 2014 May; 12():169. PubMed ID: 24885319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HE4 as a biomarker for ovarian and endometrial cancer management.
    Li J; Dowdy S; Tipton T; Podratz K; Lu WG; Xie X; Jiang SW
    Expert Rev Mol Diagn; 2009 Sep; 9(6):555-66. PubMed ID: 19732003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.
    Presl J; Novotny Z; Topolcan O; Vlasak P; Kucera R; Fuchsova R; Vrzalova J; Betincova L; Svobodova S
    Anticancer Res; 2014 Jan; 34(1):327-31. PubMed ID: 24403483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer.
    Knific T; Osredkar J; Smrkolj Š; Tonin I; Vouk K; Blejec A; Frković Grazio S; Rižner TL
    Gynecol Oncol; 2017 Oct; 147(1):126-132. PubMed ID: 28735628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant HE4 protein promotes proliferation of pancreatic and endometrial cancer cell lines.
    Lu Q; Chen H; Senkowski C; Wang J; Wang X; Brower S; Glasgow W; Byck D; Jiang SW; Li J
    Oncol Rep; 2016 Jan; 35(1):163-70. PubMed ID: 26497244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of HE4 in Endometrial Cancer and Its Clinical Significance.
    Li X; Gao Y; Tan M; Zhuang H; Gao J; Hu Z; Wang H; Zhu L; Liu J; Lin B
    Biomed Res Int; 2015; 2015():437468. PubMed ID: 26539494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human epididymis protein 4 (HE4) in benign and malignant diseases.
    Hertlein L; Stieber P; Kirschenhofer A; Krocker K; Nagel D; Lenhard M; Burges A
    Clin Chem Lab Med; 2012 Dec; 50(12):2181-8. PubMed ID: 23093276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of HE4 for ovarian cancer: a meta-analysis.
    Yu S; Yang HJ; Xie SQ; Bao YX
    Clin Chem Lab Med; 2012 Feb; 50(8):1439-46. PubMed ID: 22868811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of HE4 in ovarian cancer: inhibiting tumour cell proliferation and metastasis.
    Gao L; Cheng HY; Dong L; Ye X; Liu YN; Chang XH; Cheng YX; Chen J; Ma RQ; Cui H
    J Int Med Res; 2011; 39(5):1645-60. PubMed ID: 22117965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of serum HE4 levels throughout the normal menstrual cycle.
    Moore RG; Plante B; Hartnett E; Mitchel J; Raker CA; Vitek W; Eklund E; Lambert-Messerlian G
    Am J Obstet Gynecol; 2017 Jul; 217(1):53.e1-53.e9. PubMed ID: 28237871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.